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7. Metabolic omplications of CF 
~ Cystic Fibrosis related diabetes: the presence of microvascular 
diabetic complications 
H.U. Andersen 1, S. Lanng 2, T. Pressler 2, C. Laugesen 3, E. Mathiesen 1 .
1Dept.of Med. Endocrinology, 2Cystic Fibrosis' Unit, 3Dept. of @hthalmology, 
Rigshospitalet, Copenhagen, Denmark 
Cystic fibrosis related iabetes (CFRD) has been regarded as a mild form of diabetes 
with a low risk of severe diabetic complications. The prevalence and severity of 
CFRD increases with age, resulting in a 50% prevalence of diabetes at 30 years of 
age. 
Objective: To investigate whether microvascular complications in CFRD appear 
with a clinically relevant frequency. 
Research Design and Methods: Thirty-eight patients above 18 years of age 
with insulin treated CFRD in our department were screened for late diabetic 
complications. 
Results: Since the pharmacological treatment with i.e. cyclosporine of lungtrans- 
planted patients could influence the metabolical regulation and renal function, the 
results are given separately for non-transplanted (n 29) and transplanted (n 9) 
CF patients. Nine patients (27%) had retinopathy, two of which had proliferative 
retinopathy and needed laser treatment. Lung transplantation did not affect the 
prevalence of retinopathy. Nine out of 29 non-transplanted patients had hyperten- 
sion, 3 microalbuminuria and 1 elevated creatinine. None had macroalbuminuria. 
In transplanted patients, 8 out of 9 had hypertension, 2 had microalbuminuria and 
none had macroalbuminuria. Seven of the 9 lung transplanted patients had elevated 
plasma creatinine and severely reduced glomerular filtration rate was significantly 
more frequent. 
Conclusions: A high frequency of diabetic retinopathy was found in patients with 
insulin treated CFRD, stressing the need for regular screening. Severely impaired 
kidney function was common in lungtransplanted patients, probably secondary to 
cyclosporine treatment. 
$63 
l~ ls  earlier development of CFRD one possible reason for worse 
clinical findings in women with CFRD? 
C. K~impfert 1 , R.W Holl 2, A. Marquart 2, M. Ballmann 1 . For the CFRD Study 
Group. 1Paed. Dep. L Medical School Hanover; 2ZIBMT, University Ulm, 
Germany 
It is well known that patients with Cystic Fibrosis related Diabetes Mellitus (CFRD) 
are in worse clinical condition compared to patients without CFRD. An actual 
cross-sectional study demonstrated that only women with established CFRD have a 
significantly worse lung function than a control group without CFRD. Male CFRD- 
patients and women with newly diagnosed CFRD don't have a worse lung function. 
This cross-sectional study could not answer the question, in which age the CFRD 
was diagnosed in men respectively women and if a possible longer duration of 
CFRD could contribute to the observed gender difference. 
In a large multicentre study in Germany and Austria we followed a huge number 
of CF-patients with annual OGT% This offered the opportunity to calculate the 
mean age of first glucose disturbance and the age when CFRD was diagnosed for 
the first time. This data were calculated and compared for sex differences using 
Kapla~Meier-analysis. 
Between 2002 and 2005 we performed 2646 oral glucose-tolerance-tests in 1334 
CF-patients. In Kaplan-Meier-analysis themedian age for the first pathologic OGT- 
test was 26.2 years (1st quartile: 17.3 years) with no gender difference. CFRD 
occurred significantly earlier in female than in male patients (female 1st quartile: 
29.7 years, male 1st quartile: 35.3 years). By age of 18, diabetes was diagnosed 
in 12.5% of female compared to 4.1% of male patients based on two independent 
diabetic OGT-tests. 
The longer duration of the CFRD in female patients might be one reason for the 
worse clinical condition described in cross-sectional studies. Nevertheless it is still 
open why female patients developed CFRD earlier. 
Supported by the German Mucoviscidosis foundation and NovoNordisk. 
• Decline in lung function and BMI prior to the diagnosis of CFRD 
and the impact of gender 
J. Brown 1 , C. Elston 1 , R. Driver 2, G.A. Hitman 2, L.M. Kuitert 1. 1Adult 
CF Service, London Chest Hospital, 2Department ofDiabetes, Royal London 
Hospital, London, UK 
Introduction: An accelerated decline in lung function and BMI can precede the 
development of CFRD by up to 6 years. A recent study suggested the earlier 
mortality was only seen in females with CFRD. 
Aims: To establish if a decline in lung function and BMI occurred prior to the 
diagnosis of CFRD and the impact of gender. 
Methods: A retrospective notes review of all patients diagnosed with CFRD after 
1985. The best value for FEV1 and BMI for each of the 6 years preceding the 
diagnosis was recorded (years 6 to 0, with year 6 as baseline). CF controls were 
matched for age and sex. Annual rate of change for FEV1 and B MI were calculated 
and compared using the students test, with significance set at 0.05. 
Results: 21 patients developed CFRD (8 female; 13 male). Mean age at diagnosis 
was 28.9 years (22.9yrs at baseline), mean FEV1 1.88L (52.1% pred), mean 
BMI 20.3. Controls mean FEV1 was 2.4L (61.4%), mean BMI 20.6. The mean 
%change in FEV1/yr in CFRD was 5.77%/yr vs. controls 1.61%/yr (p 0.003). 
The mean %change in FEV1/yr was greater in females than males ( 9.81%/yr 
vs. 3.28%/yr, p 0.002). BMI changes were small but statistically significantly 
different (mean %change/yr for CFRD +0.05 vs. controls +1.4, p 0.01). In CFRD 
males mean change in BMI/yr was +0.4 vs. 0.2 in females (p 0.02); there was 
no significant gender difference in controls. 
Conclusions: The decline in lung function prior to the diagnosis of CFRD was 
seen in females not males. BMI showed little change over time. CFRD patients did 
not improve their BMI as much as controls; again females did worse. The worse 
outcomes for females upport he CFRD mortality data previously reported. 
l • U s e  of continuous subcutaneous glucose monitoring 
system (CSGMS) in the management of CFRD: the CFRD team 
and patient perspective 
M. Butler 1 , R. Driver 2, C. Elston 1 , G.A. Hitman 2, L.M. Kuitert 1. 1Adult 
CF Service, London Chest Hospital, 2Department ofDiabetes, Royal London 
Hospital London, UK 
Introduction: Management of type 1 diabetes with insulin and the need for regular 
blood glucose monitoring is a burden for patients and adversely affects quality of 
life. Achieving ood glycemic ontrol can be difficult and CSGMS is regularly used 
to adjust insulin therapy. In CFRD the burden of treatment is even greater, the need 
for good glycemic ontrol just as important, and the value of CSGMS in improving 
control unclear. 
Aim: To assess the value of CSGMS in determining insulin therapy and staff and 
patient response to this. 
Methods: All patients with CFRD underwent CSGMS as part of routine clinical 
care, recording insulin use, meals and snacks. Insulin (basal/bolus) therapy was 
modified according to the results. Patients answered a simple questionnaire about 
their experience of CSGMS. 
Results: 10 patients underwent CSGMS. Analysis of CSGMS led most often to a 
reduction in basal insulin and/or addition of short-acting insulin to cover snacks. 
Diabetic ontrol improved in 9 patients: mean HbAlc before 7.69%, after 7.62%, the 
number of patients experiencing hypos fell from 6 to 3 (2-substantially less hypos), 
and 6 patients gained weight. Thus staff felt CSGMS was useful in improving 
glycemic control. 80% of patients had problems wearing the device (unable to 
bathe/noisy/uncomfortable). All patients felt using the device and feedback on the 
results helped them to understand their diabetes better, particularly the relevance of 
good glycemic ontrol to their CE Most felt empowered to manage their disease 
better and were more optimistic and positive about diabetes management. 
Conclusions: CSGMS is well received by patients and staff, and useful in improving 
glycemic ontrol. 
